<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26768">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949415</url>
  </required_header>
  <id_info>
    <org_study_id>RES-008</org_study_id>
    <nct_id>NCT01949415</nct_id>
  </id_info>
  <brief_title>An Optional Investigation of Biomarkers of Efficacy</brief_title>
  <official_title>An Optional Investigation of Biomarkers of Efficacy in TH002 Clinical Study Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Topstone Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and
      fabric. Like many other allergens, exposure to HDMA in sensitised patients is associated
      with poorer lung function, greater medication requirements and more asthma symptoms as well
      as chronic rhinosinusitis symptoms. In contrast to other allergens, there is evidence that
      HDMA leads to the development of asthma, in addition to exacerbating pre-existing asthma in
      HDM-sensitised patients.

      ToleroMune House Dust Mite (TM-HDM) is being developed for the treatment of HDM allergy.

      Study TH002 evaluated the efficacy, safety and tolerability of TM-HDM. This study will
      identify cellular, proteomic or genetic biomarkers of efficacy to TM-HDM treatment in TH002
      study participants
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To identify cellular, proteomic or genetic biomarkers of efficacy to ToleroMune House Dust Mite (TM-HDM) treatment in TH002 study participants.</measure>
    <time_frame>1 Day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of subjects who completed TH002 and have been dosed with
        either placebo or the 12 nmol dose in the TH002 study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously randomised into study TH002, completed the study and received either
             placebo or the 12 nmol dose in TH002.

        Exclusion Criteria:

          -  Subjects who have received allergen or peptide immunotherapy during the last 12
             months (other than TM-HDM)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Topstone Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 4Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>September 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>House Dust Mite</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>ToleroMune</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
